JAK2 and thrombocytosis disease: Clinically, patients with PV harboring the JAK2V617F mutation exhibit pancytosis, including leukocytosis, thrombocytosis, and erythrocytosis, whereas those harboring the JAK2 exon 12 mutation show only an aggressive increase in red cell mass.